Predicting which HIV patients will respond better to future therapeutic vaccine

July 18, 2014

A new study suggests that HIV patients with a higher level of a particular biomarker, or a measurable indicator found in the blood, may respond more favourably to an experimental immune activating vaccine.

Experts at St George's, University of London, and Norwegian company, Bionor Pharma Researchers, believe the findings might lead to a more customised vaccine for certain , which potentially might permit them to come off antiretrovirals, drugs used to treat HIV.

The research found that the , Vacc-4x, reduced the amount of virus circulating in the body by more than half in patients with higher levels of the particular biomarker compared to those with lower levels.

Professor Angus Dalgleish, of St George's, University of London, said: "In spite of very effective drugs against HIV these need to be taken daily and have significant side-effects.

"The ability to replace this daily medication with a vaccine that allows several months of being off medication, not to mention the enormous financial gains that would be delivered to health services, is a step closer with these preliminary results."

Further study will be needed to confirm the results.

These new results were announced today (July 18) at the AIDS 2014 Conference in Melbourne, Australia.

The results come from a collaborative project between St George's, University of London and Bionor Pharma.

In the UK nearly 78,000 people were receiving specialist care for HIV in 2012.

Explore further: Scientists discover how a killer fungus attacks HIV patients

Related Stories

Scientists discover how a killer fungus attacks HIV patients

April 23, 2014
Researchers have discovered that a type of white blood cell carries a deadly fungus into the brains of HIV positive patients, causing meningitis which kills more than 600,000 people a year.

Research may be beating HIV, but a vaccine remains distant

July 11, 2014
Three decades since the onset of the infection in a global population, HIV care and treatment is looking very different. Given the difficulties involved, it is remarkable that having developed good treatments, the global ...

Past HIV vaccine trials reveal new path to success

March 19, 2014
A multi-national research team led by Duke Medicine scientists has identified a subclass of antibodies associated with an effective immune response to an HIV vaccine.

Spanish hospital to trial new HIV treatment

December 9, 2013
Researchers at a Spanish hospital announced Monday they will start trials next year of a therapeutic vaccine for patients who already have HIV, the virus that causes AIDS.

Durable end to AIDS will require HIV vaccine development

February 5, 2014
Broader global access to lifesaving antiretroviral therapies and wider implementation of proven HIV prevention strategies could potentially control and perhaps end the HIV/AIDS pandemic. However, a safe and at least moderately ...

HIV vaccine research must consider various immune responses

April 3, 2014
Last year, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, held a scientific meeting to examine why certain investigational HIV vaccines may have increased susceptibility ...

Recommended for you

Paris spotlight on latest in AIDS science

July 21, 2017
Some 6,000 HIV experts gather in Paris from Sunday to report advances in AIDS science as fading hopes of finding a cure push research into new fields.

Scientists elicit broadly neutralizing antibodies to HIV in calves

July 20, 2017
Scientists supported by the National Institutes of Health have achieved a significant step forward, eliciting broadly neutralizing antibodies (bNAbs) to HIV by immunizing calves. The findings offer insights for HIV vaccine ...

Heart toxin reveals new insights into HIV-1 integration in T cell genome

July 20, 2017
Human immunodeficiency virus (HIV)-1 may have evolved to integrate its genetic material into certain immune-cell-activating genes in humans, according to new research published in PLOS Pathogens.

Scientists capture first high-resolution image of key HIV protein transitional state

July 13, 2017
A new, three-dimensional snapshot of HIV demonstrates the radical structural transformations that enable the virus to recognize and infect host cells, according to a new study led by scientists at The Scripps Research Institute ...

Barrier to autoimmune disease may open door to HIV, study suggests

July 11, 2017
Researchers from the University of Colorado School of Medicine have discovered that a process that protects the body from autoimmune disease also prevents the immune system from generating antibodies that can neutralize the ...

Team tests best delivery mode for potential HIV vaccine

June 20, 2017
For decades, HIV has successfully evaded all efforts to create an effective vaccine but researchers at The Scripps Research Institute (TSRI) and the La Jolla Institute for Allergy and Immunology (LJI) are steadily inching ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.